

Remco A Koster

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4544093/publications.pdf>

Version: 2024-02-01

34
papers

1,128
citations

489802

18
h-index

466096

32
g-index

34
all docs

34
docs citations

34
times ranked

1092
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of decreased LC-MS/MS run-times on small molecule bioanalysis. <i>Bioanalysis</i> , 2021, 13, 409-413.	0.6	0
2	Have we got "patient-centric sampling" right?. <i>Bioanalysis</i> , 2020, 12, 869-872.	0.6	1
3	UHPLC-MS/MS method for iohexol determination in human EDTA and lithium-heparin plasma, human urine and in goat- and pig EDTA plasma. <i>Bioanalysis</i> , 2020, 12, 981-990.	0.6	3
4	Volumetric absorptive microsampling and dried blood spot microsampling vs. conventional venous sampling for tacrolimus trough concentration monitoring. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1687-1695.	1.4	41
5	Performance of a web-based application measuring spot quality in dried blood spot sampling. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1846-1853.	1.4	14
6	Very complex internal standard response variation in LC-MS/MS bioanalysis: root cause analysis and impact assessment. <i>Bioanalysis</i> , 2019, 11, 1693-1700.	0.6	8
7	A volumetric absorptive microsampling LC-MS/MS method for five immunosuppressants and their hematocrit effects. <i>Bioanalysis</i> , 2019, 11, 495-508.	0.6	43
8	Clinical application of a dried blood spot assay for sirolimus and everolimus in transplant patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1854-1862.	1.4	24
9	Quality Assessment of Dried Blood Spots from Patients With Tuberculosis from 4 Countries. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 714-718.	1.0	13
10	Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot-Based Methods for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 409-430.	1.0	188
11	Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs. <i>Clinical Mass Spectrometry</i> , 2019, 14, 34-45.	1.9	17
12	Simple and robust LC-MS/MS analysis method for therapeutic drug monitoring of micafungin. <i>Bioanalysis</i> , 2018, 10, 877-886.	0.6	9
13	Determination of levofloxacin in human serum using liquid chromatography tandem mass spectrometry. <i>Journal of Applied Bioanalysis</i> , 2018, 4, 16-25.	0.2	9
14	Method for Therapeutic Drug Monitoring of Voriconazole and its Primary Metabolite Voriconazole-N-oxide in Human Serum using LC-MS/MS. <i>Journal of Applied Bioanalysis</i> , 2018, 4, 114-123.	0.2	5
15	Substance use in individuals with mild to borderline intellectual disability: A comparison between self-report, collateral-report and biomarker analysis. <i>Research in Developmental Disabilities</i> , 2017, 63, 151-159.	1.2	20
16	Dried blood spot validation of five immunosuppressants, without hematocrit correction, on two LC-MS/MS systems. <i>Bioanalysis</i> , 2017, 9, 553-563.	0.6	42
17	Clinical Validation of Simultaneous Analysis of Tacrolimus, Cyclosporine A, and Creatinine in Dried Blood Spots in Kidney Transplant Patients. <i>Transplantation</i> , 2017, 101, 1727-1733.	0.5	49
18	Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1211-e1218.	1.1	25

#	ARTICLE	IF	CITATIONS
19	Reply to Verhaeghe et al: Table 1.. Clinical Infectious Diseases, 2016, 63, 146-147.	2.9	0
20	LC-MS/MS for Therapeutic Drug Monitoring of anti-infective drugs. TrAC - Trends in Analytical Chemistry, 2016, 84, 34-40.	5.8	40
21	Analysis of Remifentanyl with Liquid Chromatography-Tandem Mass Spectrometry and an Extensive Stability Investigation in EDTA Whole Blood and Acidified EDTA Plasma. Anesthesia and Analgesia, 2015, 120, 1235-1241.	1.1	14
22	What is the right blood hematocrit preparation procedure for standards and quality control samples for dried blood spot analysis?. Bioanalysis, 2015, 7, 345-351.	0.6	59
23	Dried blood spot analysis of creatinine with LC-MS/MS in addition to immunosuppressants analysis. Analytical and Bioanalytical Chemistry, 2015, 407, 1585-1594.	1.9	46
24	The performance of five different dried blood spot cards for the analysis of six immunosuppressants. Bioanalysis, 2015, 7, 1225-1235.	0.6	36
25	Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. Bioanalysis, 2015, 7, 481-495.	0.6	21
26	The relation of the number of hydrogen-bond acceptors with recoveries of immunosuppressants in DBS analysis. Bioanalysis, 2015, 7, 1717-1722.	0.6	13
27	Dried blood spot analysis; facing new challenges. Journal of Applied Bioanalysis, 2015, 1, 38-41.	0.2	7
28	The influence of the dried blood spot drying time on the recoveries of six immunosuppressants. Journal of Applied Bioanalysis, 2015, 1, 116-122.	0.2	14
29	Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS/MS method. Bioanalysis, 2014, 6, 2125-2133.	0.6	35
30	Therapeutic Drug Monitoring by Dried Blood Spot: Progress to Date and Future Directions. Clinical Pharmacokinetics, 2014, 53, 1053-1053.	1.6	16
31	Fast and Highly Selective LC-MS/MS Screening for THC and 16 Other Abused Drugs and Metabolites in Human Hair to Monitor Patients for Drug Abuse. Therapeutic Drug Monitoring, 2014, 36, 234-243.	1.0	46
32	Application of Sweat Patch Screening for 16 Drugs and Metabolites Using a Fast and Highly Selective LC-MS/MS Method. Therapeutic Drug Monitoring, 2014, 36, 35-45.	1.0	32
33	Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery. Talanta, 2013, 115, 47-54.	2.9	110
34	Robust, High-Throughput LC-MS/MS Method for Therapeutic Drug Monitoring of Cyclosporine, Tacrolimus, Everolimus, and Sirolimus in Whole Blood. Therapeutic Drug Monitoring, 2009, 31, 116-125.	1.0	128